http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 17:54:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+31++Filed+by%3A+BOURLA+ALBERT/27014049.html si-local-file:///var/storage/secattach/20260901/27014049.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+31++Filed+by%3A+BOURLA+ALBERT/27014049.html Tue, 01 Sep 2026 17:54:00 -0400 PFE http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++PFIZER+INC++++++++++++++++For%3A+Jun+30/27005548.html si-local-file:///var/storage/secattach/20260831/27005548.html http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++PFIZER+INC++++++++++++++++For%3A+Jun+30/27005548.html Mon, 31 Aug 2026 16:04:00 -0400 PFE http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+17++Filed+by%3A+Guegan+Cecile/26996913.html si-local-file:///var/storage/secattach/20260828/26996913.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+17++Filed+by%3A+Guegan+Cecile/26996913.html Fri, 28 Aug 2026 14:37:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+17++Filed+by%3A+Guegan+Cecile/26996913.html si-local-file:///var/storage/secattach/20260828/26996913.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+17++Filed+by%3A+Guegan+Cecile/26996913.html Fri, 28 Aug 2026 14:37:00 -0400 O.00000313 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html <p>Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.</p> <p>The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.</p> <p>The FDA's decision is based on previously submitted clinical, non-clinical, and real-world data supporting the safety and effectiveness of Comirnaty, along with manufacturing and http://www.streetinsider.com/FDA/FDA+approves+Pfizer-BioNTech+XFG-targeted+Covid-19+vaccine/26990467.html Thu, 27 Aug 2026 16:30:18 -0400 A.06822034 A.37485697 A.50217000 BNTX O.07073414 O.20026344 O.40932621 O.47566503 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+14++Filed+by%3A+BOURLA+ALBERT/26939159.html si-local-file:///var/storage/secattach/20260817/26939159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+14++Filed+by%3A+BOURLA+ALBERT/26939159.html Mon, 17 Aug 2026 18:15:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+14++Filed+by%3A+BOURLA+ALBERT/26939159.html si-local-file:///var/storage/secattach/20260817/26939159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+14++Filed+by%3A+BOURLA+ALBERT/26939159.html Mon, 17 Aug 2026 18:15:00 -0400 O.00000313 PFE http://www.streetinsider.com/FDA/EMA+validates+Pfizer+and+Valneva%27s+Lyme+disease+vaccine+application/26923320.html <p>Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for their investigational Lyme disease vaccine candidate, PF-07307405, and will begin its formal assessment.</p> <p>The application is based on results from the Phase 3 VALOR trial, which reported efficacy of more than 70% in preventing Lyme disease in participants aged five years and older. The vaccine was reported to be well tolerated, with no safety concerns identified in the trial.</p> <p>The VALOR trial was a multicenter, placebo-controlled, randomized, observer-blinded study conducted across sites in the U.S., http://www.streetinsider.com/FDA/EMA+validates+Pfizer+and+Valneva%27s+Lyme+disease+vaccine+application/26923320.html Fri, 14 Aug 2026 01:00:15 -0400 PFE http://www.streetinsider.com/Press+Releases/Pfizer+and+Valneva%E2%80%99s+Lyme+Disease+Vaccine+Candidate+Marketing+Authorization+Application+Validated+by+European+Medicines+Agency/26923316.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>Submission based on favorable efficacy and safety results from Phase 3 VALOR trial</i></li></ul> <p align="justify"><b>NEW YORK &amp; LYON, France, August, 14, 2026 </b>Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. </p> <p>The application is based on encouraging efficacy of more than 70% observed in the <a href="https://www.globenewswire.com/Tracker?data=94NMu-Ed2WJO2C0bL8thnlJhIOVZiX3ychd_AnC4qadVvaZeE4bN0j641mIYwIvERswiJL0fFY-ENd2VeUZkKJFFBe2j7zYzCv3g7Pzq8JF-A5P1Adf-7e8sOfl6uKTsYzbUNGg_eC751rMS1KgF6WPppxx0BM1hqEn46Yqd2SQYnSg3SJ2_QAt6X36YVo_bvmsAY514PiIRX1mir2lEJrPZvZLLpVT47Gfj0JZ5hQg=" rel="nofollow" target="_blank">Phase 3 VALOR</a> “Vaccine Against Lyme for Outdoor http://www.streetinsider.com/Press+Releases/Pfizer+and+Valneva%E2%80%99s+Lyme+Disease+Vaccine+Candidate+Marketing+Authorization+Application+Validated+by+European+Medicines+Agency/26923316.html Fri, 14 Aug 2026 01:00:00 -0400 PFE http://www.streetinsider.com/Globe+Newswire/Pfizer+and+Valneva%E2%80%99s+Lyme+Disease+Vaccine+Candidate+Marketing+Authorization+Application+Validated+by+European+Medicines+Agency/26923316.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>Submission based on favorable efficacy and safety results from Phase 3 VALOR trial</i></li></ul> <p align="justify"><b>NEW YORK &amp; LYON, France, August, 14, 2026 </b>Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. </p> <p>The application is based on encouraging efficacy of more than 70% observed in the <a href="https://www.globenewswire.com/Tracker?data=94NMu-Ed2WJO2C0bL8thnlJhIOVZiX3ychd_AnC4qadVvaZeE4bN0j641mIYwIvERswiJL0fFY-ENd2VeUZkKJFFBe2j7zYzCv3g7Pzq8JF-A5P1Adf-7e8sOfl6uKTsYzbUNGg_eC751rMS1KgF6WPppxx0BM1hqEn46Yqd2SQYnSg3SJ2_QAt6X36YVo_bvmsAY514PiIRX1mir2lEJrPZvZLLpVT47Gfj0JZ5hQg=" rel="nofollow" target="_blank">Phase 3 VALOR</a> “Vaccine Against Lyme for Outdoor http://www.streetinsider.com/Globe+Newswire/Pfizer+and+Valneva%E2%80%99s+Lyme+Disease+Vaccine+Candidate+Marketing+Authorization+Application+Validated+by+European+Medicines+Agency/26923316.html Fri, 14 Aug 2026 01:00:00 -0400 PFE http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++PFIZER+INC++++++++++++++++For%3A+Jun+30/26922279.html si-local-file:///var/storage/secattach/20260813/26922279.html http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++PFIZER+INC++++++++++++++++For%3A+Jun+30/26922279.html Thu, 13 Aug 2026 16:44:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++PFIZER+INC++++++++++++++++For%3A+Jun+30/26922279.html si-local-file:///var/storage/secattach/20260813/26922279.html http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++PFIZER+INC++++++++++++++++For%3A+Jun+30/26922279.html Thu, 13 Aug 2026 16:44:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+12++Filed+by%3A+BOURLA+ALBERT/26912695.html si-local-file:///var/storage/secattach/20260812/26912695.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+12++Filed+by%3A+BOURLA+ALBERT/26912695.html Wed, 12 Aug 2026 16:04:00 -0400 O.00000313 PFE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+12++Filed+by%3A+BOURLA+ALBERT/26912695.html si-local-file:///var/storage/secattach/20260812/26912695.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PFIZER+INC++++++++++++++++For%3A+Aug+12++Filed+by%3A+BOURLA+ALBERT/26912695.html Wed, 12 Aug 2026 16:04:00 -0400 O.00000313 PFE http://www.streetinsider.com/General+News/PFE+builds+bull+case+at+%2426+after+earnings+beat+and+insider+buys/26888642.html <p>Investing.com - Pfizer stock is trading at $26.20, up 1.51% on Friday, pressing the upper edge of a two-month base that bulls argue is coiling for a breakout.</p><p>The setup has quietly become one of the more debated large-cap pharmaceutical questions on Wall Street: after a roughly 45% decline over five years, is PFE finally cheap enough — and operationally sound enough — to own again? The evidence accumulated since Tuesday's Q2 report suggests the answer is tilting toward yes, though the path is not without landmines.</p><p>The Earnings Foundation</p><p>Pfizer's second-quarter results, reported on August 4, delivered the clearest proof yet that http://www.streetinsider.com/General+News/PFE+builds+bull+case+at+%2426+after+earnings+beat+and+insider+buys/26888642.html Fri, 07 Aug 2026 09:42:59 -0400 PFE http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2429+at+Bernstein+SocGen+Group/26888384.html Bernstein SocGen Group analyst Courtney Breen lowered the price target on Pfizer (NYSE: PFE) to $29.00 (from $30.00) while maintaining a Market Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Pfizer+%28PFE%29+PT+Lowered+to+%2429+at+Bernstein+SocGen+Group/26888384.html Fri, 07 Aug 2026 09:11:48 -0400 PFE http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html <p>Trump Administration Weighs Order On Autism And Vaccines - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Trump+Administration+Weighs+Order+On+Autism+And+Vaccines+-+Bloomberg/26884676.html Thu, 06 Aug 2026 16:36:01 -0400 GSK MRK MRNA PFE SAN